Despite a growing number of available targeted treatments, their usage in metastatic cancer is limited due to a lack of target expression information .
FETCH provides this patient specific, up-to-date treatment target information in metastatic cancer. For this, FETCH utilizes the existing technology of leukapheresis, allowing analysis of circulating tumour cells from the full blood volume.
FETCH offers investment and collaboration opportunities to improve and expand its innovative workflow.